References
- Kim S. Changes in surgical loads and economic burden of hip and knee replacements in US: 1997–2004. Arthritis Rheum.59, 481–488 (2008).
- Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133, 381S–453S (2008).
- Heit JA, Silverstein MD, Mohr DN et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch. Intern. Med.159, 445–453 (1999).
- Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.361, 1139–1151 (2009).
- Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin. Pharmacokinet.47(5), 285–295 (2008).
- Stangier J, Stahle H, Rathgen K et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J. Clin. Pharmacol.48(12), 1411–1419 (2008).
- Eriksson BI, Dahl OE, Ahnfelt L et al. Dose escalating safety study on a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J. Thromb. Haemost.2, 1573–1580 (2004).
- Eriksson BI, Dahl OE, Buller HR et al. A new oral direct thrombin inhibitor, 244 dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost.3, 103–111 (2005).
- Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, noninferiority trial. Lancet370(9591), 949–956 (2007).
- Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost.5, 2178–2185 (2007).
- Ginsberg JS, Davidson BL, Comp PC et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty24, 1–9 (2009).
- Eriksson BI, Dahl OE, Huo MH et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). Thromb. Haemost.105, 721–729 (2011).
- Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med.361, 2342–2352 (2009).